Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.xcrm.2020.100123 http://scihub22266oqcxt.onion/10.1016/j.xcrm.2020.100123 32995758!7513813!32995758     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Cell+Rep+Med 2020 ; 1 (7): 100123 Nephropedia Template TP {{tp|p=32995758|t=2020. ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens |pdf=|usr=}}{{32995758}} gab.com Text ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens JO: Cell Rep Med http://www.kidney.de/pget.php?&tw=1&pmid=32995758 #FOAvip Comprehensive understanding of the serological response to SARS-CoV-2 infection is important for both pathophysiologic insight and diagnostic development. Here, we generate a pan-human coronavirus programmable phage display assay to perform proteome-wide profiling of coronavirus antigens enriched by 98 COVID-19 patient sera. Next, we use ReScan, a method to efficiently sequester phage expressing the most immunogenic peptides and print them onto paper-based microarrays using acoustic liquid handling, which isolates and identifies nine candidate antigens, eight of which are derived from the two proteins used for SARS-CoV-2 serologic assays: spike and nucleocapsid proteins. After deployment in a high-throughput assay amenable to clinical lab settings, these antigens show improved specificity over a whole protein panel. This proof-of-concept study demonstrates that ReScan will have broad applicability for other emerging infectious diseases or autoimmune diseases that lack a valid biomarker, enabling a seamless pipeline from antigen discovery to diagnostic using one recombinant protein source. Twit Text FOAVip ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens ????Cell Rep Med http://www.kidney.de/pget.php?&tw=1&pmid=32995758 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32995758 #FOAvip English Wikipedia <ref>{{Cite pmid|32995758}}</ref> ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-2 Antigens #MMPMID32995758 Zamecnik CR; Rajan JV; Yamauchi KA; Mann SA; Loudermilk RP; Sowa GM; Zorn KC; Alvarenga BD; Gaebler C; Caskey M; Stone M; Norris PJ; Gu W; Chiu CY; Ng D; Byrnes JR; Zhou XX; Wells JA; Robbiani DF; Nussenzweig MC; DeRisi JL; Wilson MR Cell Rep Med 2020[Oct]; 1 (7): 100123 PMID32995758show ga Comprehensive understanding of the serological response to SARS-CoV-2 infection is important for both pathophysiologic insight and diagnostic development. Here, we generate a pan-human coronavirus programmable phage display assay to perform proteome-wide profiling of coronavirus antigens enriched by 98 COVID-19 patient sera. Next, we use ReScan, a method to efficiently sequester phage expressing the most immunogenic peptides and print them onto paper-based microarrays using acoustic liquid handling, which isolates and identifies nine candidate antigens, eight of which are derived from the two proteins used for SARS-CoV-2 serologic assays: spike and nucleocapsid proteins. After deployment in a high-throughput assay amenable to clinical lab settings, these antigens show improved specificity over a whole protein panel. This proof-of-concept study demonstrates that ReScan will have broad applicability for other emerging infectious diseases or autoimmune diseases that lack a valid biomarker, enabling a seamless pipeline from antigen discovery to diagnostic using one recombinant protein source. |Antibodies, Viral/blood[MESH] |Antigens, Viral/*immunology[MESH] |COVID-19 Serological Testing/*methods[MESH] |COVID-19/blood/*diagnosis[MESH] |Female[MESH] |Humans[MESH] |Male[MESH] |Middle Aged[MESH] |Peptide Library[MESH] |Protein Array Analysis[MESH] |Proteome/immunology[MESH] |Reproducibility of Results[MESH] |SARS-CoV-2/immunology/*isolation & purification[MESH] |Sensitivity and Specificity[MESH]ReScan, a Multiplex Diagnostic Pipeline, Pans Human Sera for SARS-CoV-(epmc).pdf DeepDyve Pubget Overpricing